Company / SG&A Expense
Bone Biologics Corp SG&A Expense History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.4M
FY2020
5-year range
$1.4M / $6.4M
FY2017-FY2020
Trend
-49.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $6M in FY2017 to $1M in FY2020.
Based on SEC 10-K filings.
$1M in FY2020 with a 3-year CAGR of -40.6%.
Improved from $4M to $1M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -40.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Bone Biologics Corp's sg&a expense has declined for 3 consecutive years.
- 3-year CAGR of -40.6%, indicating a declining trend.
- In FY2020, sg&a expense decreased 49.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $1.4M | -49.7% |
| FY2019 | $2.7M | -32.1% |
| FY2018 | $4.0M | -38.6% |
| FY2017 | $6.4M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026